Companies Dominating the Epigenetics Landscape
- AbbVie
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche
- GlaxoSmithKline (GSK)
- Incyte
- Jazz Pharmaceuticals
- Merck & Co.
- Novartis
- Pfizer
- Bio-Techne
- Merck KGaA
Several large drug companies include epigenetics studies within their wider cancer or other health issue programs. Moreover, a few smaller firms dedicate their entire focus to epigenetics. These efforts reflect the rapidly evolving nature of the field and its significant potential for transforming therapeutic approaches, underscoring the critical role of both large and small entities in advancing our understanding and treatment of diseases through epigenetic science.
Browse Key Market Insights with Data Illustration:
In the News
- AbbVie - AbbVie, a leading biotech firm focused on cutting-edge research, announced that as of December 1st, 2021, VENCLEXTA® (venetoclax), a drug, is now included under the Pharmaceutical Benefits Scheme (PBS). This treatment is designated for adults battling a certain form of leukemia (acute myeloid leukemia or AML) who are unable to undergo intensive chemotherapy. AML is a rapidly spreading blood cancer impacting the bone marrow and blood system. In AML, the growth of abnormal leukemia cells outpaces healthy blood cells, hindering their essential functions, such as combating infections, oxygen transport, and bleeding control. Without prompt intervention, AML can cause severe infections and additional severe health issues.
- GlaxoSmithKline (GSK) - IDEAYA and GSK are joining forces to craft new cancer cures through a cutting-edge method named "synthetic lethality." IDEAYA contributes three projects (MAT2A, Pol Theta, and Werner Helicase) poised to reach clinical trial stages within the next few years. These initiatives are already off to a solid start, with both the 3D structures mapped out and promising early results from animal tests for two of them (MAT2A and Pol Theta). This partnership meshes well with GSK’s strategic priority of exploiting synthetic lethality in its quest to forge novel cancer therapies.
